Aurigon Life Science

Executive Summary

Aurigon Life Science, founded in 2017 and headquartered in Munich, Germany, is a full-service contract research organization (CRO) supporting pharmaceutical and medical device clients across the drug development continuum. The company offers a comprehensive suite of services including pharmacology, bioanalytics, toxicology, and medical device testing, catering to startups as well as large pharma. As a privately held, pre-clinical stage CRO, Aurigon leverages its expertise to accelerate and de-risk drug development programs. The CRO market is growing steadily, driven by increasing R&D outsourcing by biopharma, and Aurigon is well-positioned with its specialized capabilities in oncology and immunology. The company’s German base provides regulatory advantages within the EU and access to a skilled talent pool. While Aurigon does not disclose financials, its focus on high-quality advisory and experimental services suggests a resilient business model with potential for client repeat business and expansion.

Upcoming Catalysts (preview)

• H2 2026Securing a multi-year contract with a top-20 pharmaceutical company65% success
• Q4 2026Completion of a new bioanalytical laboratory expansion in Munich70% success
• Q3 2026Receiving ISO 17025 accreditation for its analytical testing services80% success